Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma

Published:2016-10 Issue:5 Volume:9 Page:466-471
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Cho Jinhyun,Lee Jeeyun,Kim Jusun,Kim Seung Tae,Lee Sujin,Kim Sun Young,Ha Sang Yun,Park Cheol-Keun,Lim Ho Yeong

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference25 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Hepatocellular carcinoma;Llovet;Lancet,2003

3. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma;Yeo;J Natl Cancer Inst,2005

4. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

5. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial;Cheng;Lancet Oncol,2009

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recurrent Tuberous Sclerosis Complex/Mammalian Target of Rapamycin Mutations Define Primary Renal Hemangioblastoma as a Unique Entity Distinct From Its Central Nervous System Counterpart;American Journal of Surgical Pathology;2024-03-19

2. Metabolic reprogramming in cancer: Mechanisms and therapeutics;MedComm;2023-03-27

3. eIF4A1 Inhibitor Suppresses Hyperactive mTOR-Associated Tumors by Inducing Necroptosis and G2/M Arrest;International Journal of Molecular Sciences;2022-06-22

4. Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches;Pharmaceutics;2022-06-19

5. TSC2 Mutations Were Associated with the Early Recurrence of Patients with HCC Underwent Hepatectomy;Pharmacogenomics and Personalized Medicine;2021-02